Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (NASDAQ:BBNX), filed a Form 4 on November 13, 2026, disclosing an option exercise and same-day sale of 8,874 shares of common stock on November 11, 2026, pursuant to a Rule 10b5-1 plan.

Key Highlights

  • Option exercised: Feider exercised an employee stock option covering 8,874 shares at an exercise price of $5.10 per share on November 11, 2026.
  • Shares sold: All 8,874 shares were sold on November 11, 2026, at a weighted average price of $17.2054, with individual sale prices ranging between $17.00 and $17.55, according to the filing.
  • 10b5-1 plan: The sale was made pursuant to a Rule 10b5-1 plan adopted on July 31, 2026, as disclosed in the filing.
  • Remaining ownership: Following the transactions, Feider directly beneficially owned 159,378 shares of common stock.
  • Remaining options: Feider retains 29,695 shares underlying employee stock options with an exercise price of $5.10 and an expiration date of September 13, 2033.
  • Option vesting: According to the filing, the option shares vest in 48 equal monthly installments measured from September 14, 2023.

CFO Stephen Feider's Option Exercise and Share Sale at Beta Bionics

According to the Form 4 filed with the SEC on November 13, 2026, Stephen Feider, the Chief Financial Officer of Beta Bionics, Inc., executed two transactions on November 11, 2026. First, he acquired 8,874 shares of common stock through the exercise of an employee stock option at an exercise price of $5.10 per share, bringing his directly held beneficial ownership to 168,252 shares following that acquisition.

Immediately following the exercise, Feider disposed of all 8,874 shares in a sale coded "S" in the filing. The weighted average sale price was reported as $17.2054, with individual transaction prices ranging from $17.00 to $17.55. The filing notes that full information regarding the number of shares sold at each separate price will be provided upon request by SEC staff, the issuer, or any security holder. After the sale, Feider's directly held beneficial ownership stood at 159,378 shares of common stock.

The filing states that the sale was made pursuant to a Rule 10b5-1 plan that Feider adopted on July 31, 2026. The underlying employee stock option, with an exercise price of $5.10 and an expiration date of September 13, 2033, is disclosed as vesting in 48 equal monthly installments measured from September 14, 2023. Following the exercise, Feider retains 29,695 shares underlying the same option series. The Form 4 was signed by Thomas Sohn as Attorney-in-Fact on November 13, 2026.

What Was Disclosed

Beta Bionics CFO Stephen Feider reported the exercise of 8,874 stock options at $5.10 per share and the same-day sale of all resulting shares at a weighted average of $17.2054 on November 11, 2026, under a pre-established 10b5-1 trading plan.